Caution over NICE cholesterol drug recommendation

A leading medical charity has urged caution today after the UK regulator NICE recommended two new medications for people with cholesterol conditions that put them at increased risk of heart attack or stroke.

The draft guidance recommends alirocumab (Praluent, Sanofi) and evolucumab (Repatha, Amgen) for adults with primary hypercholesterolaemia or mixed dyslipidaemia.

But The British Heart Foundation (BHF) has called for more research into the long-term safety of the drugs before final guidance is published.

NICE says because both drugs are expensive – with alirocumab costing more than £4,000 per patient per year and £350 for ezetemibe – it only recommends them if they are provided at the discounted price agreed with the companies.

The committees heard that alirocumab reduced levels of LDL-cholesterol by up to 62% compared with placebo, and up to 40% compared with ezetimibe, which is commonly used to lower cholesterol.

Unlike statins, alirocumab and evolocumab work by blocking the PCSK9 preotin, allowing the liver to remove cholesterol from the blood.

However, the BHF has warned that the drugs’ long-term safety is still unknown and urged further research before they are recommended more widely.

Professor Peter Weissberg, medical director at the British Heart Foundation, said: “The new PCSK9 inhibitors approved for use by NICE are a new and exciting way to reduce harmful cholesterol levels.

“However, because their long term safety is still unknown, and they are yet to show reduced risk of heart attack, their use is currently restricted to patients with dangerously high cholesterol levels despite treatment with statins.

“This new class of drugs is undergoing intensive clinical investigation. Guidelines are likely to change in the future as more information is revealed surrounding their safety and effectiveness.”

NICE says that until final guidance is issued, NHS bodies should make decisions locally on the funding of specific treatments.

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index